SwePub
Sök i SwePub databas

  Utökad sökning

AND är defaultoperator och kan utelämnas

Träfflista för sökning "AMNE:(MEDICAL AND HEALTH SCIENCES Clinical Medicine Clinical Laboratory Medicine) ;lar1:(lu)"

Sökning: AMNE:(MEDICAL AND HEALTH SCIENCES Clinical Medicine Clinical Laboratory Medicine) > Lunds universitet

  • Resultat 1-10 av 384
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Schöll, Michael, 1980, et al. (författare)
  • Biomarkers for tau pathology.
  • 2019
  • Ingår i: Molecular and cellular neurosciences. - : Elsevier BV. - 1095-9327 .- 1044-7431. ; 97, s. 18-33
  • Forskningsöversikt (refereegranskat)abstract
    • The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein characterizes 80% of all dementia disorders, the most common neurodegenerative disorders. These so-called tauopathies are hitherto not curable and their diagnosis, especially at early disease stages, has traditionally proven difficult. A keystone in the diagnosis of tauopathies was the development of methods to assess levels of tau protein in vivo in cerebrospinal fluid, which has significantly improved our knowledge about these conditions. Tau proteins have also been measured in blood, but the importance of tau-related changes in blood is still unclear. The recent addition of positron emission tomography ligands to visualize, map and quantify tau pathology has further contributed with information about the temporal and spatial characteristics of tau accumulation in the living brain. Together, the measurement of tau with fluid biomarkers and positron emission tomography constitutes the basis for a highly active field of research. This review describes the current state of biomarkers for tau biomarkers derived from neuroimaging and from the analysis of bodily fluids and their roles in the detection, diagnosis and prognosis of tau-associated neurodegenerative disorders, as well as their associations with neuropathological findings, and aims to provide a perspective on how these biomarkers might be employed prospectively in research and clinical settings.
  •  
3.
  • Bäcklund, Nils, et al. (författare)
  • Salivary cortisol and cortisone in diagnosis of Cushing's syndrome - a comparison of six different analytical methods
  • 2023
  • Ingår i: Clinical Chemistry and Laboratory Medicine. - : Walter de Gruyter. - 1434-6621 .- 1437-4331. ; 61:10, s. 1780-1791
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: Salivary cortisol and cortisone at late night and after dexamethasone suppression test (DST) are increasingly used for screening of Cushing's syndrome (CS). We aimed to establish reference intervals for salivary cortisol and cortisone with three liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques and for salivary cortisol with three immunoassays (IAs), and evaluate their diagnostic accuracy for CS.Methods: Salivary samples at 08:00 h, 23:00 h and 08:00 h after a 1-mg DST were collected from a reference population (n=155) and patients with CS (n=22). Sample aliquots were analyzed by three LC-MS/MS and three IA methods. After establishing reference intervals, the upper reference limit (URL) for each method was used to calculate sensitivity and specificity for CS. Diagnostic accuracy was evaluated by comparing ROC curves.Results: URLs for salivary cortisol at 23:00 h were similar for the LC-MS/MS methods (3.4-3.9 nmol/L), but varied between IAs: Roche (5.8 nmol/L), Salimetrics (4.3 nmol/L), Cisbio (21.6 nmol/L). Corresponding URLs after DST were 0.7-1.0, and 2.4, 4.0 and 5.4 nmol/L, respectively. Salivary cortisone URLs were 13.5-16.6 nmol/L at 23:00 h and 3.0-3.5 nmol/L at 08:00 h after DST. All methods had ROC AUCs =0.96.Conclusions: We present robust reference intervals for salivary cortisol and cortisone at 08:00 h, 23:00 h and 08:00 h after DST for several clinically used methods. The similarities between LC-MS/MS methods allows for direct comparison of absolute values. Diagnostic accuracy for CS was high for all salivary cortisol and cortisone LC-MS/MS methods and salivary cortisol IAs evaluated.
  •  
4.
  • Alaridah, Nader, et al. (författare)
  • Transmission dynamics study of tuberculosis isolates with whole genome sequencing in southern Sweden
  • 2019
  • Ingår i: Scientific Reports. - : Nature Publishing Group. - 2045-2322. ; 9
  • Tidskriftsartikel (refereegranskat)abstract
    • Epidemiological contact tracing complemented with genotyping of clinical Mycobacterium tuberculosis isolates is important for understanding disease transmission. In Sweden, tuberculosis (TB) is mostly reported in migrant and homeless where epidemiologic contact tracing could pose a problem. This study compared epidemiologic linking with genotyping in a low burden country. Mycobacterium tuberculosis isolates (n = 93) collected at Scania University Hospital in Southern Sweden were analysed with the standard genotyping method mycobacterial interspersed repetitive units-variable number tandem repeats (MIRU-VNTR) and the results were compared with whole genome sequencing (WGS). Using a maximum of twelve single nucleotide polymorphisms (SNPs) as the upper threshold of genomic relatedness noted among hosts, we identified 18 clusters with WGS comprising 52 patients with overall pairwise genetic maximum distances ranging from zero to nine SNPs. MIRU-VNTR and WGS clustered the same isolates, although the distribution differed depending on MIRU-VNTR limitations. Both genotyping techniques identified clusters where epidemiologic linking was insufficient, although WGS had higher correlation with epidemiologic data. To summarize, WGS provided better resolution of transmission than MIRU-VNTR in a setting with low TB incidence. WGS predicted epidemiologic links better which could consolidate and correct the epidemiologically linked cases, avoiding thus false clustering.
  •  
5.
  • Marcisauskas, Simonas, 1988, et al. (författare)
  • Univariate and classification analysis reveals potential diagnostic biomarkers for early stage ovarian cancer Type 1 and Type 2
  • 2019
  • Ingår i: Journal of Proteomics. - : Elsevier BV. - 1874-3919 .- 1876-7737. ; 196, s. 57-68
  • Tidskriftsartikel (refereegranskat)abstract
    • Biomarkers for early detection of ovarian tumors are urgently needed. Tumors of the ovary grow within cysts and most are benign. Surgical sampling is the only way to ensure accurate diagnosis, but often leads to morbidity and loss of female hormones. The present study explored the deep proteome in well-defined sets of ovarian tumors, FIGO stage I, Type 1 (low-grade serous, mucinous, endometrioid; n = 9), Type 2 (high-grade serous; n = 9), and benign serous (n = 9) using TMT–LC–MS/MS. Data are available via ProteomeXchange with identifier PXD010939. We evaluated new bioinformatics tools in the discovery phase. This innovative selection process involved different normalizations, a combination of univariate statistics, and logistic model tree and naive Bayes tree classifiers. We identified 142 proteins by this combined approach. One biomarker panel and nine individual proteins were verified in cyst fluid and serum: transaldolase-1, fructose-bisphosphate aldolase A (ALDOA), transketolase, ceruloplasmin, mesothelin, clusterin, tenascin-XB, laminin subunit gamma-1, and mucin-16. Six of the proteins were found significant (p <.05) in cyst fluid while ALDOA was the only protein significant in serum. The biomarker panel achieved ROC AUC 0.96 and 0.57 respectively. We conclude that classification algorithms complement traditional statistical methods by selecting combinations that may be missed by standard univariate tests. Significance: In the discovery phase, we performed deep proteome analyses of well-defined histology subgroups of ovarian tumor cyst fluids, highly specified for stage and type (histology and grade). We present an original approach to selecting candidate biomarkers combining several normalization strategies, univariate statistics, and machine learning algorithms. The results from validation of selected proteins strengthen our prior proteomic and genomic data suggesting that cyst fluids are better than sera in early stage ovarian cancer diagnostics.
  •  
6.
  • Berglund, Eva Caroline, et al. (författare)
  • A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias
  • 2022
  • Ingår i: Frontiers in Medicine. - Lausanne, Switzerland : Frontiers Media SA. - 2296-858X. ; 9, s. 1-9
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS), with the ability to provide comprehensive genomic information, have become the focal point of research interest as novel techniques that can support precision diagnostics in routine clinical care of patients with various cancer types, including hematological malignancies. This national multi-center study, led by Genomic Medicine Sweden, aims to evaluate whether combined application of WGS and WTS (WGTS) is technically feasible and can be implemented as an efficient diagnostic tool in patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In addition to clinical impact assessment, a health-economic evaluation of such strategy will be performed. Methods and Analysis: The study comprises four phases (i.e., retrospective, prospective, real-time validation, and follow-up) including approximately 700 adult and pediatric Swedish AML and ALL patients. Results of WGS for tumor (90×) and normal/germline (30×) samples as well as WTS for tumors only will be compared to current standard of care diagnostics. Primary study endpoints are diagnostic efficiency and improved diagnostic yield. Secondary endpoints are technical and clinical feasibility for routine implementation, clinical utility, and health-economic impact. Discussion: Data from this national multi-center study will be used to evaluate clinical performance of the integrated WGTS diagnostic workflow compared with standard of care. The study will also elucidate clinical and health-economic impacts of a combined WGTS strategy when implemented in routine clinical care. Clinical Trial Registration: [https://doi.org/10.1186/ISRCTN66987142], identifier [ISRCTN66987142].
  •  
7.
  • Andersson, Axel G, et al. (författare)
  • Large difference but high correlation between creatinine and cystatin C estimated glomerular filtration rate in Mesoamerican sugarcane cutters.
  • 2022
  • Ingår i: Occupational and environmental medicine. - : BMJ. - 1470-7926 .- 1351-0711. ; 79:7, s. 497-502
  • Tidskriftsartikel (refereegranskat)abstract
    • To explore the relationship between creatinine and cystatin C based estimated glomerular filtration rate (eGFR) in actively working sugarcane cutters.This cohort study included 458 sugarcane cutters from Nicaragua and El Salvador. Serum samples were taken before and at end of harvest seasons and analysed for creatinine and cystatin C. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulas were used to calculate eGFRs based on creatinine (eGFRcr), cystatin C (eGFRcys) and both creatinine and cystatin C (eGFRcrcys) at each time point. Bland-Altman plots and paired t-tests were used to compare the difference between eGFRcr and eGFRcys, and the difference in eGFRs between before and at end of the harvest seasons.The mean eGFRcr was higher than eGFRcys in both cohorts; absolute difference 22mL/min/1.73 m2 (95%CI 21 to 23) in Nicaragua and 13mL/min/1.73 m2 (95%CI 11 to 15) in El Salvador. Correlations between eGFRcr and eGFRcys were high, with r=0.69, 0.77 and 0.67 in Nicaragua at pre-harvest, end-harvest and cross-harvest, and r=0.89, 0.89 and 0.49 in El Salvador.Creatinine increases among heat-stressed workers reflect reduced glomerular filtration as estimated using eGFRcys, a marker independent of muscle mass and metabolism. The discrepancy between eGFRcr and eGFRcys may indicate reduced glomerular filtration of larger molecules and/or systemic bias in CKD-EPI performance in this population.
  •  
8.
  • Qvarfordt, Mikaela, Doktorand, 1979-, et al. (författare)
  • Bioelectrical impedance and lung function  - associations with gender and central obesity : results of the EpiHealth study
  • 2024
  • Ingår i: BMC Pulmonary Medicine. - : BioMed Central (BMC). - 1471-2466. ; 24:1
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundObesity is a major public health concern associated with various health problems, including respiratory impairment. Bioelectrical impedance (BIA) is used in health screening to assess body fat. However, there is no consensus in healthcare on how body fat should be assessed in relation to lung function. In this study, we aimed to investigate how BIA in relation to waist circumference contribute, using data from a large Swedish population study.MethodsA total of 17,097 participants (aged 45–75 years) were included in the study. The relationships between fat mass, waist circumference, and lung function were analysed using weighted quantile sum regression.ResultsIncreased fat mass was significantly associated with decreased lung function (FEV1, FVC) in both sexes. Also, the influence of trunk fat and waist circumference on FVC and FEV1 differed by sex: in males, waist circumference and trunk fat had nearly equal importance for FVC (variable weights of 0.42 and 0.41), whereas in females, trunk fat was significantly more important (variable weights 0.84 and 0.14). For FEV1, waist circumference was more important in males, while trunk fat was more significant in females (variable weights male 0.68 and 0.28 and 0.23 and 0.77 in female).ConclusionsOur results suggest that trunk fat should be considered when assessing the impact of adipose tissue on lung function and should potentially be included in the health controls.
  •  
9.
  • Borrelli, P., et al. (författare)
  • AI-based detection of lung lesions in F-18 FDG PET-CT from lung cancer patients
  • 2021
  • Ingår i: Ejnmmi Physics. - : Springer Science and Business Media LLC. - 2197-7364. ; 8:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Background[F-18]-fluorodeoxyglucose (FDG) positron emission tomography with computed tomography (PET-CT) is a well-established modality in the work-up of patients with suspected or confirmed diagnosis of lung cancer. Recent research efforts have focused on extracting theragnostic and textural information from manually indicated lung lesions. Both semi-automatic and fully automatic use of artificial intelligence (AI) to localise and classify FDG-avid foci has been demonstrated. To fully harness AI's usefulness, we have developed a method which both automatically detects abnormal lung lesions and calculates the total lesion glycolysis (TLG) on FDG PET-CT.MethodsOne hundred twelve patients (59 females and 53 males) who underwent FDG PET-CT due to suspected or for the management of known lung cancer were studied retrospectively. These patients were divided into a training group (59%; n = 66), a validation group (20.5%; n = 23) and a test group (20.5%; n = 23). A nuclear medicine physician manually segmented abnormal lung lesions with increased FDG-uptake in all PET-CT studies. The AI-based method was trained to segment the lesions based on the manual segmentations. TLG was then calculated from manual and AI-based measurements, respectively and analysed with Bland-Altman plots.ResultsThe AI-tool's performance in detecting lesions had a sensitivity of 90%. One small lesion was missed in two patients, respectively, where both had a larger lesion which was correctly detected. The positive and negative predictive values were 88% and 100%, respectively. The correlation between manual and AI TLG measurements was strong (R-2 = 0.74). Bias was 42 g and 95% limits of agreement ranged from -736 to 819 g. Agreement was particularly high in smaller lesions.ConclusionsThe AI-based method is suitable for the detection of lung lesions and automatic calculation of TLG in small- to medium-sized tumours. In a clinical setting, it will have an added value due to its capability to sort out negative examinations resulting in prioritised and focused care on patients with potentially malignant lesions.
  •  
10.
  • Cullen, Nicholas (författare)
  • The future of clinical trials for Alzheimer's disease. A blood-based biomarker perspective
  • 2022
  • Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
    • Objectives: The primary objective was to investigate the utility of blood-basedbiomarkers of amyloid, tau, and neurodegeneration for (i) screening, (ii)enrichment, and (iii) tracking response to treatment in clinical trials of Alzheimer’sdisease.Methods: Longitudinal, participant-level data used in these studies was drawn fromthe Swedish BioFINDER study and the ADNI study. Participants were classified ascognitively unimpaired, mild cognitive impairment, or Alzheimer’s diseasedementia. For screening, logistic regression was used to predict amyloid PET statusin CU individuals from plasma Aβ42/Aβ40, APOE status, and age. For enrichment,Linear mixed effects models were used to predict longitudinal cognitive decline andfuture risk of AD dementia in CU individuals or in MCI individuals from a basicmodel (age, sex, education, APOE status) and varying combinations of blood-basedbiomarkers (plasma Aβ42/Aβ40, plasma pTau181, plasma pTau217, plasma NfL).For treatment response, plasma NfL was measured longitudinally in MCI or ADpatients and properties such as slope, inter-subject variability, and intra-subjectvariability were calculated. Plasma NfL was then compared with MRI andcognition.Results: The amyloid PET screening model had an AUC of 0.87, with a significantindependent effect for plasma Aβ42/Aβ40 and APOE status, but not age. This modelwas estimated to reduce total cost of recruiting 500 amyloid-positive CUparticipants by 31 – 42%, depending on the relative cost of amyloid scanning toplasma measurement. For enrichment, plasma pTau181 and pTau217 had the largesteffect on predicting cognitive decline in CU and MCI participants, with Aβ42/Aβ40and NfL having significant effects in some scenarios. Using these biomarkers in aclinical trial could reduce the required sample size of a clinical trial in CUparticipants by up to 70%. Finally, plasma NfL was shown to have worse theoreticalperformance as a trial progression marker compared to MRI-based measures,primarily due to its high within-subject variability. NfL compared better to cognitivemeasures as endpoints.Discussion: The future of AD clinical trials will likely leverage plasma biomarkersfor initial screening. Their utility for enrichment and tracking treatment responsestill needs to be evaluated in the context of other biomarkers measured in CSF, MRI,or PET. The plasma ATN biomarkers evaluated here all appear to be independentlyuseful, but there is strong potential for more plasma biomarkers to be added to sucha panel.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 384
Typ av publikation
tidskriftsartikel (322)
doktorsavhandling (22)
forskningsöversikt (22)
konferensbidrag (12)
bokkapitel (3)
bok (2)
visa fler...
rapport (1)
visa färre...
Typ av innehåll
refereegranskat (349)
övrigt vetenskapligt/konstnärligt (34)
populärvet., debatt m.m. (1)
Författare/redaktör
Micke, Patrick (33)
Brunnström, Hans (26)
Jirström, Karin (19)
Mattsson, Johanna So ... (16)
Hultberg, Björn (15)
Hansson, Oskar (14)
visa fler...
Grubb, Anders (13)
Pontén, Fredrik (12)
Nodin, Björn (11)
La Fleur, Linnea (11)
Planck, Maria (10)
Sundström, Christer (9)
Ehinger, Mats (9)
Backman, Max (8)
Djureinovic, Dijana (8)
Mezheyeuski, Artur (7)
Jerkeman, Mats (7)
Lindskog, Cecilia (7)
Olsson, Martin L (7)
Englund, Elisabet (7)
Kolstad, Arne (7)
Zetterberg, Henrik (7)
Laurell, Anna (6)
Laurell, Thomas (6)
Blennow, Kaj (6)
Marko-Varga, György (6)
Koyi, Hirsh (6)
Brandén, Eva (6)
Björk, Jonas (6)
Staaf, Johan (6)
Ashton, Nicholas J. (6)
Rasmussen, Magnus (6)
Schöll, Michael (6)
Nyman, Ulf (6)
Delabie, Jan (6)
Jönsson, Per (5)
Glimelius, Bengt (5)
Larsson, Anders (5)
Abrahamson, Magnus (5)
Geisler, Christian H (5)
Malm, Johan (5)
Ralfkiaer, Elisabeth (5)
Karjalainen-Lindsber ... (5)
Grønbæk, Kirsten (5)
Leandersson, Karin (5)
Palmqvist, Lars, 196 ... (5)
Lindström, Veronica (5)
Edlund, Karolina (5)
Bläckberg, Anna (5)
Nilson, Bo (5)
visa färre...
Lärosäte
Uppsala universitet (89)
Karolinska Institutet (74)
Göteborgs universitet (54)
Linköpings universitet (28)
Umeå universitet (24)
visa fler...
Örebro universitet (13)
Chalmers tekniska högskola (12)
Malmö universitet (8)
Kungliga Tekniska Högskolan (6)
Linnéuniversitetet (5)
Stockholms universitet (4)
Högskolan Kristianstad (2)
Jönköping University (2)
Högskolan i Skövde (2)
Högskolan i Borås (2)
RISE (2)
Högskolan i Halmstad (1)
Mittuniversitetet (1)
Högskolan Dalarna (1)
Blekinge Tekniska Högskola (1)
visa färre...
Språk
Engelska (383)
Kinesiska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (384)
Teknik (42)
Naturvetenskap (24)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy